Corporate Profile
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cell therapy being evaluated for its potential to preserve kidney function in patients with advanced CKD and diabetes who are at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Minimum 15 minutes delayed. Source: LSEG
Events
Jun 4, 2026 7:35 AM EDT
Jan 14, 2026 8:15 AM PST
Nov 17 - Nov 20, 2025